Volume 1.34 | Sep 10

Prostate Cell News 1.34, September 10, 2010.


Constitutively Active Androgen Receptor Splice Variants Expressed in Castration-Resistant Prostate Cancer Require Full-Length Androgen Receptor 
To explore the range of potential androgen receptor (AR) splice variants lacking the ligand binding domain, researchers screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. [Proc Natl Acad Sci USA]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Caltech Scientists Create New Process to “Program” Cancer Cell Death
Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. [Press release from the California Institute of Technology discussing online prepublication in Proceedings of the National Academy of Sciences USA]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Selective Cell Death Mediated by Small Conditional RNAs
Here, researchers describe small conditional RNAs that undergo hybridization chain reactions to induce cell death via an innate immune response if and only if a cognate mRNA cancer marker is detected within a cell. [Proc Natl Acad Sci USA]

Epithelial Hic-5/ARA55 Expression Contributes to Prostate Tumorigenesis and Castrate Responsiveness
To determine the role of epithelial Hic-5 in prostate cancer progression and castration responsiveness, researchers compared LNCaP cells having Hic-5 stably expressed with the parental LNCaP cells following tissue recombination xenografts with mouse prostate stromal cells. [Oncogene]

Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists
To better characterize expression of tumoral luteinizing hormone-releasing hormone (LH-RH) receptors, specimens of prostate cancer from various cohorts of patients were analyzed. [Clin Cancer Res]

The Tocopherol Transfer Protein Sensitizes Prostate Cancer Cells to Vitamin E
Researchers hypothesized that over-expression of the tocopherol transfer protein, a vitamin E-binding protein that regulates tocopherol status, will sensitize prostate cancer cells to the anti-proliferative actions of the vitamin. [J Biol Chem]

Embelin Suppresses Osteoclastogenesis Induced by RANKL and Tumor Cells In Vitro Through Inhibition of the NF-KappaB Cell Signaling Pathway
Researchers investigated whether embelin could inhibit osteoclastogenesis-associated bone loss induced by RANKL and by tumor cells in vitro. [Mol Cancer Res]


Metronomic Administration of Zoledronic Acid and Taxotere Combination in Castration Resistant Prostate Cancer Patients – Phase I ZANTE Trial
Docetaxel and zoledronic acid are effective in patients with hormone resistant prostate cancer (HRPC) with bone metastases. A phase I clinical trial of metronomic administration of Zoledronic Acid and Taxotere combination (ZANTE trial) in two different sequences was conducted in HRPC. [Cancer Biol Ther]

Sleep and Daily Functioning During Androgen Deprivation Therapy for Prostate Cancer
This study assessed sleep in 60 prostate cancer patients taking androgen deprivation therapy with wrist actigraphy and daily diaries for 7 days. [Eur J Cancer Care]

Antiangiogenic and Antitumor Activity of LP-261, A Novel Oral Tubulin Binding Agent, Alone and in Combination with Bevacizumab
Here, researchers report the results of testing in multiple mouse xenograft models and angiogenesis assays, along with bioavailability studies. [Invest New Drugs]


STEMSOFT® Software Inc. Licenses StemLab® Software to Arizona’s Celebration Stem Cell Centre
STEMSOFT Software Inc., the leading provider of software solutions for the cell therapy and transplant community, is pleased to announce the licensing of StemLab, the leading cell therapy and cord blood banking laboratory software, to the Celebration Stem Cell Centre in Gilbert, Arizona. [STEMSOFT Software Inc. Press Release]

CytRx Initiates Phase II Clinical Trial with Bafetinib in Advanced Prostate Cancer
CytRx Corporation, a biopharmaceutical company specializing in oncology, announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer. [CytRx Corporation Press Release]

Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria
Ortho Biotech Oncology Research & Development announced that it has unblinded the Phase III study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [Johnson and Johnson Press Release]

EVENTS (Listed by Date)

Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
Los Angeles, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada

International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.